Prostate cancer is a complex and biologically heterogeneous disease that is not adequately assessed with conventional imaging alone. Molecular imaging with positron emission tomography (PET) is poised to fill this unmet need through noninvasive probing of the multiple molecular and cellular processes that are active in prostate cancer patients.
INTRODUCTION
Prostate cancer is a biologically heterogeneous disease across the spectrum of its clinical states [1] , and is thus challenging to treat. Successful management is further confounded by the disease-specific limitations of conventional imaging [2] . Positron emission tomography (PET) carries a distinct advantage over conventional imaging in its unique ability to noninvasively interrogate metabolic and molecular processes in vivo. These processes include alterations in glucose, amino acid and fatty acid metabolism, receptor status, cellular proliferation, tumor hypoxia and blood flow. Several PET tracers are active in early-stage and late-stage prostate cancer (see Table 1 ). Among these, F18-fluorodeoxyglucose (FDG), Choline (C11 and F18 labeled) and sodium F18-fluoride (NaF) have been studied most extensively. Choline is emerging from the vast cloud of data (quite heterogeneous, akin to the disease itself) as a valuable tool for assessment of early prostate cancer, whereas FDG and NaF appear to have greater utility in advanced disease.
C11 AND F18 CHOLINE
The two radiolabeled forms of choline are generally considered to provide similar information, with the advantage of C11 labeled choline being minimal urinary excretion, whereas the F18 compound is a better fit for commercial use, owing to its longer half-life (110 vs. 20 min for C11). Choline PET is increasingly utilized in the Eastern Hemisphere for evaluation of prostate cancer; however, in many studies the patient populations and states of disease are quite heterogenous. A recent systematic review [3 && ] of 37 studies noted several sources of variation affecting the reported performance of F18-choline PET, underscoring the need for rigorously standardized prospective imaging trials. Nonetheless, it is apparent that choline PET is a rational and viable modality for evaluating prostate cancer, particularly in its early stages.
A major challenge for PET imaging of localized prostate cancer is the difficulty in detecting small lesions and in discriminating between benign and malignant processes. This is a well known challenge for FDG, but also exists for other tracers including choline-PET. In an elegant study, Souvatzoglou et al. [4 && ] recently evaluated 43 patients who underwent radical prostatectomy within 31 days after C11choline PET/CT. Transaxial images and histologic specimens were analyzed by comparing the respective slices. Not surprisingly, the authors found that small focal tumors (<5 mm) and rind-like tumors were poorly detected on PET, whereas larger well defined tumors were evident on PET (Fig. 1 ). In addition, standardized uptake values (SUV)max failed to distinguish between cancer (median SUVmax 4.9), benign prostatic hypertrophy (median SUVmax 4.5) and prostatitis (median SUVmax 3.9), P ¼ 0.102 and P ¼ 0.054, respectively.
The greatest value of the choline agents seems to be in the setting of rising PSA following definitive local therapy. By definition, patients with 'biochemical relapse' have a rising PSA level as the only manifestation of their disease [5] . The goal of molecular imaging with PET in this setting is to localize foci of recurrent disease that are unrecognized clinically or on conventional imaging (e.g., small lymph nodes that do not meet size criteria on standard CT or MRI, or disease in bone marrow that is not recognizable on CT). The main purpose here is to distinguish between local, regional or distant disease recurrence, because the treatment will vary (e.g., irradiation to prostate bed vs. hormonal or chemotherapy). Choline uptake in prostate cancer is presumed to correlate with tumor volume as reflected by PSA levels. In a report on 63 patients categorized in biochemical recurrence, 35 (56%) patients had abnormal scans [6] . Recurrent disease KEY POINTS C11-choline and F18-choline PET are useful for restaging of prostate cancer; uptake appears to be correlated with prostate-specific antigen (PSA) kinetics in patients with recurrent disease.
F18-FDG PET and NaF-PET are valuable in advanced disease, especially for assessing bone metastases.
F18-16b-fluoro-5a-dihydrotestosterone (FDHT) PET noninvasively assesses the status of the androgen receptor (AR) expression in the setting of castrate disease.
Prostate-specific membrane antigen targeted PET tracers are proposed to reflect the effects of AR inhibition on downstream signaling, and are in the early stages of clinical development.
Prospective, rigorously controlled, clinical imaging trials are needed to establish the optimal role of PET in prostate cancer. could be localized in 36% of patients with PSA-value less than 1 ng/ml, 43% with PSA-value 1 to less than 2 ng/ml, 62% with PSA-value 2 to less than 3 ng/ml and 73% with PSA-value at least 3 ng/ml. The detection rate was not influenced by concurrent antiandrogen therapy. Other investigators have demonstrated a strong link between PSA kineticsincluding PSA doubling time (PSADT) and velocity (PSAV) -and abnormal choline PET/CT findings. Shorter doubling time and higher PSAV reflect the rate of tumor cell proliferation. Giovacchini et al. [7] studied 170 patients with biochemical relapse following radical prostatectomy, C11-choline PET/CT was positive in 75 of 170 patients (44%). The percentage of patients with positive C11-choline PET/CT was 27% for PSADT more than 6 months, 61% for PSADT between 3 and 6 months and 81% for PSADT less than 3 months. Pathologic uptake in the skeleton was seen in 52% of patients with PSADT less than 3 months and only in 3% of patients with PSADT more than 6 months. More recently, the same group showed a positive correlation with PSAV in the same patient population [8 & ]. Patients with positive C11-choline PET/CT (n ¼ 75) had significantly (P < 0.05) higher PSAV than patients with negative scans (n ¼ 95) (6.93 AE 13.08 vs. 1.23 AE 2.03 ng/ml per year). The percentage of patients with positive C11-choline PET/CT was 21% for PSAV less than 1 ng/ml per year, 56% for PSAV between 1 and 2 ng/ml per year, and 76% for PSAV more than 2 ng/ml per year. These and other studies [9,10 & ] clearly demonstrate a relationship between choline uptake and PSA kinetics; however, it is worth noting that the patient populations studied do not strictly qualify for 'biochemical relapse', as many of the PET-positive lesions were also present on conventional imaging.
SODIUM F18-FLUORIDE
Bone metastases are the primary cause of morbidity and mortality in progressive prostate cancer, eventually developing in 80-90% of patients with metastatic disease, either alone or in conjunction with less frequent visceral metastases [11] . Bone disease is notoriously difficult to assess by conventional radiography and computed tomography (CT). In fact, the osteoblastic variety, most commonly found in prostate cancer patients, is considered a nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors [12] . Scintigraphic techniques have long been the mainstay for assessing bone disease. Tc99m-methylene diphosphonate (MDP) and similar single-photon radiolabeled phosphate analogues are incorporated into the hydroxyapatite crystalline lattice and collagen matrix [13] . Uptake of MDP is a function of blood supply, rate of bone turnover or osteoblastic activity, quantity of mineralized bone, capillary permeability, fluid pressure and local acid/base balance. Bone scintigraphy is highly sensitive for osteogenic activity and allows for quick assessment of the entire skeleton. There are several limitations: bone scan findings depict derivative changes rather than the tumor itself; regression of disease is difficult to discern due to lingering radiotracer uptake in healing bone; and response assessment is confounded by the flare phenomenon, a major obstacle that can occur up to 12 weeks posteffective treatment [14] .
In recent years, NaF has re-emerged in the form of PET as a radiotracer for imaging bone metastases [15] . It was originally used for bone imaging with conventional gamma cameras applying a high energy collimator, yielding to poor resolution, and was then largely replaced by Tc99m-labeled bone tracers, which were more suitable for imaging with a conventional gamma camera [16] . The mechanism of NaF uptake is similar to that of the phosphonates. Advantages of NaF over MDP include its higher affinity for bone [17] , allowing for earlier imaging time with better image quality, which is also a product of the superior imaging characteristics of PET (Fig. 2) . Several studies to date have suggested that NaF performs better than MDP for the assessment of osteoblastic metastases, particularly when combined with the anatomic information derived from CT. Notably, Even-Sapir et al. [18] compared planar bone scintigraphy, bone SPECT, NaF-PET, and NaF-PET/CT in patients with localized, high-risk or metastatic prostate cancer. The reported sensitivity and specificity for detection of bone lesions was higher for NaF-PET/CT (100 and 100%, respectively) than for planar bone scanning (70 and 57%), SPECT (92 and 82%) or NaF-PET alone (100 and 62%). These results appear to favor NaF-PET/CT over conventional bone scintigraphy; however, limitations of the study include the mixed patient population and lack of a true standard of reference. Although NaF-PET is widely considered superior to MDP, no prospective studies have yet demonstrated an incremental benefit in staging or patient management; it is unclear whether NaF will provide more meaningful information (possibly based on quantitative assessment) regarding treatment response and disease progression than the conventional bone scan. Additionally, it is uncertain whether quantitation of NaF uptake in bone lesions, using SUV, confers prognostic information. The information derived from a conventional planar bone scan can be reduced to a single quantitative parameter, termed the bone scan index (BSI) [19] , a measure of the fractional volume of skeletal tumor burden. BSI derived from conventional bone scans is prognostic of survival [20, 21, 22 & ], and its value as an indicator of response or progression is under investigation [23 && ]. Manual BSI measurements are relatively reproducible, but are tedious to perform. An automated platform for BSI calculation that generates reproducible results within seconds was recently shown to correlate well with manually derived BSI scores [24,22 & ]. With the increasing availability of NaF-PET it remains to be seen whether the BSI can be optimized even further by the three-dimensional and quantitative properties of PET imaging.
Further experience with NaF-PET is needed before it is able to supplant conventional single photon bone scans, which are less expensive and more widely available. With the recent decision of the Centers for Medicare and Medicaid Services to reimburse sites participating in the National Oncologic PET Registry (NOPR) for NaF-PET scans, a wealth of data are expected to surface in the coming months and years.
F18-FLUORODEOXYGLUCOSE
In 2008, the NOPR published results on the clinical impact of FDG-PET [25, 26] . The registry found that FDG-PET influenced management of prostate cancer patients in 35-45% of cases across clinical indications, similar to other cancers, despite the widely held notion that FDG is of limited value in prostate cancer. It is true that FDG-PET is of not the optimal modality for assessing organ-confined prostate cancer, owing to the low glycolytic activity of many tumors, and due to technical factors such as interference by physiologic, hyperplastic or inflammatory-type FDG uptake in the prostate, and high-excreted activity in the adjacent urinary bladder. However, FDG-PET does play an important role in more advanced disease states [27] .
Schöder et al. [28] compared the performance of FDG-PET/CT and conventional imaging in 91 patients with PSA relapse following prostatectomy. The standard of reference included biopsy or clinical and imaging follow-up. PET was true positive in 28 of 91 (31%) patients, showing isolated disease in the prostate bed (n ¼ 3) or metastatic disease with (n ¼ 2) or without (n ¼ 23) simultaneous disease in the prostate bed. Mean PSA was higher in FDG-positive than in FDG-negative patients (9.5 AE 2.2 vs 2.1 AE 3.3 ng/ ml). PSA of 2.4 ng/ml and PSA velocity of 1.3 ng/ml per year provided the best trade-off between sensitivity (80%; 71%) and specificity (73%; 77%) of PET in a receiver operating curve analysis. Combination with other clinical parameters in a multivariate analysis did not improve disease prediction. In this study, there were only two patients in whom other imaging studies showed isolated local recurrence or metastatic disease.
Bone scanning, whether with NaF-PET or conventional single photon agents, remains an indirect method of imaging bone metastases. Many sclerotic lesions detected on bone scan, including NaF-PET, are in reality dormant or treated. Furthermore, lytic or marrow-based lesions are not readily detectable on bone scan due to lack of bone turnover. FDG-PET, on the contrary, directly assesses tumor metabolism in bone. The value of FDG for assessment of bone metastases in castration resistant prostate cancer (CRPC) was specifically addressed by our group [21] . In this study, 43 Clinical experience shows that FDG-PET can be applied for response assessment in patients with metastatic disease undergoing hormonal therapy or chemotherapy [29, 30] . Preliminary data suggest that this is also possible with the choline tracers, however, larger prospective studies are lacking.
FUTURE DIRECTIONS
Molecular imaging probes that target antigens and receptors specifically expressed by prostate cancer cells may eventually be transformative biomarkers for disease management and drug development.
Such PET agents are particularly relevant for navigating the biologic heterogeneity of advanced disease.
Androgen receptor probes
The AR signaling axis is implicated as a driving force in the development and progression of CRPC, justifying the need for novel antiandrogen therapies [31 & ]. AR expression and binding capacity can be assessed noninvasively with F18-FDHT, an analog of dihydrotestosterone (DHT) [32] . As endogenous DHT (the primary AR ligand) competes with FDHT for AR binding, the tracer is most suitably applied in patients with castrate disease, which is characterized by low circulating testosterone levels (<50 ng/dl) [33, 34] . In our experience with total-lesion analyses [35 & ] of paired FDG and FDHT-PET scans in metastatic CRPC, we have seen diverse patterns of uptake, including FDG/FDHT concordance, FDG predominance and FDHT predominance (Fig. 3 ). These unique phenotypes may have implications for risk stratification and personalization of therapeutic strategies. The potential role of FDHT-PET as a pharmacodynamic marker was recently demonstrated in the context of a therapeutic trial for a next-generation AR-targeted therapy. In this phase 1-2 study of MDV3100, a competitive AR inhibitor, a clear-cut reduction in uptake ($20-100%) was seen in all 22 patients evaluated with FDHT-PET during therapy, with a suggestion of dose dependence and a saturation point prior to reaching the maximum tolerated dose [36] . Of note, these FDHT 'responses' did not necessarily correlate with clinical response. At this time, it remains unclear whether therapyrelated modulation of FDHT uptake can predict clinical outcomes.
Prostate-specific membrane antigen probes
FDHT uptake reflects AR ligand-receptor interaction, but the dynamics of downstream AR signaling are perhaps better captured by other molecular imaging probes. In particular, J591 is an antibody to an epitope on the extracellular domain of prostatespecific membrane antigen (PSMA) that is promising for both imaging and radioimmunotherapy purposes [37] . PET imaging with J591 is proposed to reflect the downstream effects of AR inhibition, given that PSMA expression is downregulated by androgen administration and upregulated by androgen deprivation [38, 39] . An in-human imaging trial of Zr89-labeled J591 (Zr89-DFO-huJ591 [40] ) is currently underway at our institution, and a Cu64labeled version of the antibody is in preclinical development [41 & ]. Other PSMA-targeted tracers are currently being developed by the group at John's Hopkins University [42] . Together, AR-axis imaging agents promise to increase our understanding of the biology and escape mechanisms of prostate cancer, hopefully with implications for novel therapies.
CONCLUSION
Multiple PET tracers are now available to aid in the detection and management of prostate cancer across the clinical spectrum of the disease. Prospective clinical imaging trials using various PET tracers, individually or in combination, rigorously controlled for clinical state, therapy and well defined clinical endpoints are needed to establish the optimal role of PET in prostate cancer, just as they are crucial in drug development [43 && ].
